SEC Form 4 · accession 0001562180-16-001290
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey M Jonas
Officer — See Remarks · Director
Period of report
Jan 7, 2016
Accepted (ET)
Jan 7, 2016 · 4:54 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 31, 2015 | P | 226 | $49.56 | A | 81,226 | D | |
| Common Stock | Jan 7, 2016 | M | 20,000 | $0.45 | A | 101,226 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $0.45 | Jan 7, 2016 | M | 20,000 | D | — | Aug 12, 2023 | Common Stock | 20,000 | 400,360 | D |
Explanation of responses
- F1Common shares acquired under the Company's Employee Share Purchase Plan (ESPP).
- F2The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2011 Stock Option and Incentive Plan. The option shall vest in full on August 12, 2017, subject to continued service through such date.